Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast® f/e 31 January 2022

Pearce IP BioBlast® f/e 31 January 2022

18 Jan 22 | Alvotech announced $21 million in additional commitments for private placement (PIPE) of Oaktree II common stock.  Alvotech and Oaktree Acquisition Corp. II previously announced in December 2021 that they had entered into a pre IPO merger agreement. ...
Pearce IP BioBlast® f/e 31 January 2022

Pearce IP BioBlast® w/e 14 January 2022

10 Jan 22 | CA | Alvotech and JAMP Pharma announced that Health Canada has approved Simlandi (high-concentration, citrate-free biosimilar adalimumab). 11 Jan 22 | EU | Orion Corporation and CuraTeQ Biologics announced an expansion to their biosimilar distribution...
Pearce IP BioBlast® f/e 31 January 2022

Pearce IP BioBlast® w/e 07 January 2022

30 Dec 21 | US | Biocon Biologics announced that the US Court of Appeals for the Federal Circuit Court has upheld the US Patent and Trademark Appeal Board’s decisions of unpatentability for five device patents for Sanofi’s Lantus® (insulin glargine) SoloSTAR® as well...
Pearce IP BioBlast® f/e 31 January 2022

Pearce IP BioBlast® 31 December 2021

20 Dec 21 | US | Sandoz announced that it has submitted a BLA to the FDA for a proposed biosimilar trastuzumab. 20 Dec 21 | US | The FDA approved Eli Lilly’s Rezvlogar® (biosimilar insulin glargine). 20 Dec 21 | US | Coherus announced that the FDA has approved...